A detailed history of Jane Street Group, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Jane Street Group, LLC holds 94,911 shares of EXAS stock, worth $5.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
94,911
Previous 429,673 77.91%
Holding current value
$5.52 Million
Previous $18.2 Million 64.4%
% of portfolio
0.0%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$42.43 - $70.83 $14.2 Million - $23.7 Million
-334,762 Reduced 77.91%
94,911 $6.46 Million
Q2 2024

Aug 14, 2024

BUY
$41.33 - $74.26 $3.51 Million - $6.31 Million
84,938 Added 24.64%
429,673 $18.2 Million
Q1 2024

May 15, 2024

BUY
$56.27 - $73.77 $7.78 Million - $10.2 Million
138,262 Added 66.96%
344,735 $23.8 Million
Q4 2023

Feb 14, 2024

BUY
$59.06 - $75.72 $6.82 Million - $8.74 Million
115,452 Added 126.84%
206,473 $15.3 Million
Q3 2023

Nov 14, 2023

SELL
$65.94 - $99.04 $3.21 Million - $4.82 Million
-48,677 Reduced 34.84%
91,021 $6.21 Million
Q2 2023

Aug 14, 2023

SELL
$62.68 - $95.05 $1.08 Million - $1.63 Million
-17,155 Reduced 10.94%
139,698 $13.1 Million
Q1 2023

May 15, 2023

SELL
$47.19 - $70.77 $2.65 Million - $3.98 Million
-56,252 Reduced 26.4%
156,853 $10.6 Million
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $3.99 Million - $6.99 Million
131,462 Added 161.02%
213,105 $10.6 Million
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $42,104 - $65,020
1,317 Added 1.64%
81,643 $2.65 Million
Q2 2022

Aug 16, 2022

SELL
$35.61 - $76.23 $1.45 Million - $3.11 Million
-40,732 Reduced 33.65%
80,326 $3.16 Million
Q1 2022

May 17, 2022

SELL
$57.56 - $82.54 $6.37 Million - $9.14 Million
-110,674 Reduced 47.76%
121,058 $8.47 Million
Q4 2021

Feb 15, 2022

BUY
$72.5 - $100.68 $10.1 Million - $14 Million
138,943 Added 149.74%
231,732 $18 Million
Q3 2021

Nov 16, 2021

BUY
$90.24 - $124.05 $2.24 Million - $3.08 Million
24,863 Added 36.6%
92,789 $8.86 Million
Q2 2021

Aug 16, 2021

SELL
$93.66 - $139.27 $1.41 Million - $2.1 Million
-15,071 Reduced 18.16%
67,926 $8.44 Million
Q1 2021

May 18, 2021

SELL
$116.57 - $155.01 $3.11 Million - $4.14 Million
-26,719 Reduced 24.35%
82,997 $10.9 Million
Q4 2020

Feb 17, 2021

BUY
$99.61 - $142.12 $7.03 Million - $10 Million
70,588 Added 180.4%
109,716 $14.5 Million
Q3 2020

Nov 17, 2020

BUY
$72.92 - $102.01 $1.26 Million - $1.76 Million
17,216 Added 78.57%
39,128 $3.99 Million
Q2 2020

Aug 17, 2020

BUY
$55.75 - $92.75 $832,236 - $1.38 Million
14,928 Added 213.75%
21,912 $1.91 Million
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $6.69 Million - $18.4 Million
-176,399 Reduced 96.19%
6,984 $405,000
Q4 2019

Feb 14, 2020

BUY
$77.66 - $99.74 $7.84 Million - $10.1 Million
101,017 Added 122.64%
183,383 $17 Million
Q3 2019

Nov 14, 2019

BUY
$90.37 - $122.49 $5.88 Million - $7.97 Million
65,074 Added 376.32%
82,366 $7.44 Million
Q2 2019

Aug 15, 2019

SELL
$89.51 - $118.04 $7.6 Million - $10 Million
-84,952 Reduced 83.09%
17,292 $2.04 Million
Q1 2019

May 16, 2019

BUY
$61.98 - $96.5 $5.35 Million - $8.33 Million
86,304 Added 541.43%
102,244 $8.86 Million
Q4 2018

Feb 15, 2019

SELL
$56.04 - $82.66 $540,505 - $797,255
-9,645 Reduced 37.7%
15,940 $1.01 Million
Q3 2018

Nov 14, 2018

SELL
$48.29 - $80.6 $13.9 Million - $23.1 Million
-286,973 Reduced 91.81%
25,585 $2.02 Million
Q2 2018

Aug 15, 2018

BUY
$37.84 - $69.96 $11.6 Million - $21.4 Million
306,101 Added 4740.61%
312,558 $18.7 Million
Q1 2018

May 15, 2018

SELL
$39.82 - $57.53 $530,482 - $766,414
-13,322 Reduced 67.35%
6,457 $260,000
Q4 2017

Feb 15, 2018

BUY
$46.49 - $60.51 $580,846 - $756,011
12,494 Added 171.5%
19,779 $1.04 Million
Q3 2017

Nov 14, 2017

BUY
$37.05 - $47.12 $269,909 - $343,269
7,285
7,285 $343,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.